Manfred Groeppel Net Worth

The estimated Net Worth of Manfred Groeppel is at least $506 Thousand dollars as of 20 July 2020. Manfred Groeppel owns over 5,650 units of Immunic stock worth over $423,822 and over the last 5 years Manfred sold IMUX stock worth over $82,377.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Manfred Groeppel IMUX stock SEC Form 4 insiders trading

Manfred has made over 1 trades of the Immunic stock since 2020, according to the Form 4 filled with the SEC. Most recently Manfred sold 5,650 units of IMUX stock worth $82,377 on 20 July 2020.

The largest trade Manfred's ever made was selling 5,650 units of Immunic stock on 20 July 2020 worth over $82,377. On average, Manfred trades about 1,413 units every 0 days since 2019. As of 20 July 2020 Manfred still owns at least 278,830 units of Immunic stock.

You can see the complete history of Manfred Groeppel stock trades at the bottom of the page.

What's Manfred Groeppel's mailing address?

Manfred's mailing address filed with the SEC is 1200 AVENUE OF THE AMERICAS, SUITE 200, , NEW YORK, NY, 10036.

Insiders trading at Immunic

Over the last 5 years, insiders at Immunic have traded over $174,861 worth of Immunic stock and bought 176,506 units worth $558,583 . The most active insiders traders include Barclay A Phillips, Joerg Neermann, and Duane Nash. On average, Immunic executives and independent directors trade stock every 74 days with the average trade being worth of $15,244. The most recent stock trade was executed by Daniel Vitt on 26 February 2024, trading 14,000 units of IMUX stock currently worth $18,340.

What does Immunic do?

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

Complete history of Manfred Groeppel stock trades at Immunic

Immunic executives and stock owners

Immunic executives and other stock owners filed with the SEC include:

• Daniel Vitt,
  President, Chief Executive Officer, Director
• Andreas Muehler,
  Chief Medical Officer
• Manfred Groppel,
  Chief Operating Officer
• Dr. Daniel Vitt,
  CEO, Pres & Director
• Dr. Andreas Muehler Ph.D., M.D.,
  Chief Medical Officer
• Glenn Whaley,
  VP of Fin. and Principal Financial & Accounting Officer
• Dr. Duane D. Nash M.B.A., M.D., J.D., M.B.A,
  Exec. Chairman
• Jan Van den Bossche,
  Independent Director
• Jorg Neermann,
  Independent Director
• Vincent Ossipow,
  Independent Director
• Tamar Howson,
  Independent Director
• Barclay Phillips,
  Independent Director
• Jessica Breu,
  IR Contact Officer
• Hella Kohlhof,
  Chief Scientific Officer
• Glenn Whaley,
  Vice President Finance, Principal Financial and Accounting Officer
• Patrick Walsh,
  Chief Bus. Officer
• Inderpal Singh,
  Gen. Counsel
• Dr. Hella Kohlhof,
  Chief Scientific Officer
• Dr. Manfred Gröppel,
  Co-Founder & COO
• Jason Tardio,
  President and COO
• Richard Alan Rudick,
  Director
• Sanjay S Patel,
  Chief Financial Officer
• Joerg Neermann,
  Director
• Manfred Groeppel,
  Chief Operating Officer
• Duane Nash,
  Executive Chairman
• Monika Maria Toernsen,
  Director
• Simona Skerjanec,
  Director